» Articles » PMID: 33767579

Basal-like Breast Cancer with Low TGFβ and High TNFα Pathway Activity is Rich in Activated Memory CD4 T Cells and Has a Good Prognosis

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2021 Mar 26
PMID 33767579
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Basal-like breast cancer (BLBC) is a type of high-grade invasive breast cancer with high risk of recurrence, metastases, and poor survival. Immune activation in BLBC is a key factor that influences both cancer progression and therapeutic response, although its molecular mechanisms are not well clarified. In this study, we examined five cancer immunity-related pathways (IFNα, IFNγ, STAT3, TGFβ and TNFα) in four large independent breast cancer cohorts ( = 6,381) and their associations with the prognosis of breast cancer subtypes. Activities of the 5 pathways were calculated based on corresponding pathway signatures and associations between pathways and clinical outcomes were examined by survival analysis. Among the five PAM50-based subtypes, BLBC had the highest IFNα, IFNγ, TNFα pathway activities, and the lowest TGFβ activity. The IFNα, IFNγ, TNFα pathway activities were negatively correlated with BLBC recurrence. In contrast, positive association and no association with BLBC recurrence were observed for TGFβ and STAT3 pathways, respectively. TNFα/TGFβ pathway combination improved the prediction of recurrence and chemotherapy response of BLBCs. Immune cell subset analysis in BLBC showed that M0, M1 and M2 macrophage levels were associated with either TNFα or TGFβ pathways, whereas the level of activated memory CD4 T cells were associated with both pathways. Moreover, this T cell subset was most abundant in BLBCs with low TGFβ and high TNFα pathway activities. These results suggested that cooperation of TNFα and TGFβ signaling may be involved in the regulation of memory T cells and anti-cancer immunity in BLBCs. Our data also demonstrate that TNFα/TGFβ pathway combination may represent a better biomarker for BLBC prognosis and clinical management.

Citing Articles

Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer.

Tian J, Li Y, Tong Y, Zhang Y, Zhao T, Kang Y Front Oncol. 2025; 15:1503300.

PMID: 39931080 PMC: 11807824. DOI: 10.3389/fonc.2025.1503300.


Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.

Vlahopoulos S Int J Mol Sci. 2024; 25(16).

PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.


Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.

Liang W, Yang X, Li X, Wang P, Zhu Z, Liu S Aging (Albany NY). 2024; 16(9):7596-7621.

PMID: 38742936 PMC: 11131999. DOI: 10.18632/aging.205763.


Construction of a prognostic model based on memory CD4+ T cell-associated genes for lung adenocarcinoma and its applications in immunotherapy.

Li Y, Ye X, Huang H, Cao R, Huang F, Chen L CPT Pharmacometrics Syst Pharmacol. 2024; 13(5):837-852.

PMID: 38594917 PMC: 11098152. DOI: 10.1002/psp4.13122.


Prognostic Significance of Tumor-Associated Inflammation in Renal Cell Carcinoma.

Kovaleva O, Podlesnaya P, Mochalnikova V, Kushlinskii N, Khromykh L, Kalinina A Bull Exp Biol Med. 2024; 176(3):382-385.

PMID: 38340200 DOI: 10.1007/s10517-024-06028-9.


References
1.
Haibe-Kains B, Desmedt C, Loi S, Culhane A, Bontempi G, Quackenbush J . A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012; 104(4):311-25. PMC: 3283537. DOI: 10.1093/jnci/djr545. View

2.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

3.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

4.
Agius E, Lacy K, Vukmanovic-Stejic M, Jagger A, Papageorgiou A, Hall S . Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med. 2009; 206(9):1929-40. PMC: 2737169. DOI: 10.1084/jem.20090896. View

5.
Rodriguez-Pinilla S, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J . Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12(5):1533-9. DOI: 10.1158/1078-0432.CCR-05-2281. View